KidneyCAN is dedicated to accelerating kidney cancer research.
Our advocacy for the DOD Kidney Cancer Research Program resulted in appropriations of $40 million in fiscal year 2020 for kidney cancer research. In 2016, this number was $0.
Our Kidney Cancer Research Summit brings translational researchers in kidney cancer together in an annual collaborative meeting. Additionally, KidneyCAN’s “Rock the Cure” events have raised over $1,000,000 toward private research support.
KidneyCAN is proud to announce the second annual Kidney Cancer Research Summit, a meeting focused on basic and translational science, as well as cutting edge translational research. This work is fueled by the funding from the Department of Defense CDMRP – KCRP.
The Kidney Cancer Research Summit (#KCRS20) was scheduled for October 22nd-23rd in Philadelphia, Pennsylvania. Given the complications of COVID-19, we are now planning for a virtual conference to be held on the same dates.
Join us as we continue to fight for a cure! Registration for this event is now open for Academic/Research attendees and Industry Representatives. Questions? Contact us at [email protected].
If you missed #KCRS19, you can review the presentation content here.
“This is what started as a grassroots meeting for the entire RCC community, focusing on science, ultimate collaboration, and inclusiveness. All in the hope of helping our patients live better, live longer, and dream of the cure. Why not? Isn’t that what we all want if we get this disease?
I feel this is the beginning of something very, very special.”
“It’s one of the most exciting things I’ve ever participated in. We’re bringing together clinicians, physician scientists, and bench scientists to talk about kidney cancer research. The goal is to invigorate the science and spur breakthroughs.”
Thinking Outside the Tumor: Tumor Microenvironment and Epigenetics
Moderated by Eric Jonasch & Monty Pal
Kinase Signaling and Extracellular Matrix Proteolysis in Kidney Cancer
Chromatin Dysregulation and Metabolism Disorder in Kidney Cancer
Novel Methods of Drug Delivery
Moderated by Robert Uzzo & Michael Mitchell
Overcoming Biological Barriers (Michael Mitchell)
Single Cell Sequencing Strategies in Kidney Cancer
Moderated by Payal Kapur & Sabina Signoretti
Single Cell Architecture of Mitochondrial DNA Mutations in RCC (Eduard Reznik)
Scientific Mentoring Session Powered by the American Urological Association
Novel Checkpoint Inhibitors and Cellular Immunotherapy
Moderated by Hans Hammers & Charles Drake
Is VISTA:VSIG3 an Actionable Immune Checkpoint Target (Kathleen Mahoney)
Identification of a New Immune Checkpoint Pathway in RCC (Rupal Bhatt)
Development and Potentials for ImmunoPET Imaging (David Leung)
HERV-E TCR Transduced Autologous T Cells (Rosa Nadal)
Overview of Cellular Therapies: CAR-T (Regina Young, introduction by Naomi Haas)
Design of Dual Targeted CAR-T Cells to Improve RCC Treatment Safety (Wayne Marasco)
Moderated by Michael Atkins & Marie Carlo
Predictive Biomarkers for Nivolumab Treatment in Metastatic Renal Cell Carcinoma from Checkmate-25 (Sabina Signoretti & Toni Choueiri)
Predictive Biomarkers for VEGF Inhibitors in RCC (Maxine Sun)
Biomarkers: Where Do We Go from Here? (Brian Rini)
Bridging Academia and Industry Through Biomarker Work in RCC (Paul Robbins)
Translational Variants in Rare Kidney Cancers
Moderated by Marston Linehan & Kim Rathmell
Novel Function of the Tumor Suppressor FLCN in Rare Kidney Cancer (Mehdi Mollapour)
Chromophobe RCC: New Insights (Elizabeth Henske)
Novel Mechanism of Pathogenesis for Renal Medullary Carcinoma (Pavlos Msaouel)
Therapeutic Targeting TFE3 in Translocation Renal Cell Carcinoma (Roberto Pili & Nur Damayanti)
Papillary RCC (Brian Shuch, with Nizar Tannir)
[wd_hustle id=”email” type=”embedded”]